Advertisement


Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN

2015 NCCN Annual Conference

Advertisement

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early days of NCCN, controversies that surrounded the first meeting, oncologists’ embrace of the guidelines, and how the organization has evolved over the past 20 years.



Related Videos

Skin Cancer

John A. Thompson, MD, on Treatment Options for Advanced Melanoma

John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the latest immunotherapeutics for advanced melanoma, including pembrolizumab, trametinib, nivolumab, and dabrafenib.

Lung Cancer

Leora Horn, MD, MSc, on Targeted and Emerging Therapies for Metastatic NSCLC

Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.

Gastroesophageal Cancer

Hans Gerdes, MD, on Endoscopic Therapies for Early-Stage Esophageal Cancers

Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.

Multiple Myeloma

Kenneth C. Anderson, MD, on Multiple Myeloma: Current Treatment Approaches and Future Directions

Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.

Bladder Cancer

Peter E. Clark, MD, on a Guideline Update in the Management of Bladder Cancer

Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.

Advertisement

Advertisement



Advertisement